The Limited Times

Now you can see non-English news...

Vaccines against Covid-19: "Presenting a new target is very interesting from an immune point of view"


INTERVIEW – Infectiologist and hospital practitioner at Cochin Hospital Odile Launay is the first signatory of a study carried out by the AP-HP and published in the New England Journal of Medicine which compares the effectiveness of vaccines from GSK-Sanofi and that of Pfizer/BioNTech when they...


- What products have you tested?



We compared the Pfizer/BioNTech vaccine, already on the market, with two Sanofi-GSK products currently being validated by the health authorities.

This is a more traditional technology than messenger RNA, known as “recombinant proteins”.

To sum up, Sanofi produces virus spikes in bioreactors

(proteins that form small spikes on its surface, editor's note)

which will serve as training targets for the immune system.

And to stimulate the body's response and recruit immune cells to the injection site, the company combines them with an adjuvant produced by its partner GSK.

Sanofi has produced two types of spikes: those of the original Wuhan virus, and those of the Beta variant

(initially called the "South African variant")


This gives rise to two separate vaccines, one containing only “Wuhan” spikes and the other a mixture of the spikes of the two variants.

What tests have you...

This article is for subscribers only.

You have 77% left to discover.

Pushing back the limits of science is also freedom.

Keep reading your article for €0.99 for the first month


Already subscribed?


Source: lefigaro

All tech articles on 2022-07-04

You may like

Business 2022-07-17T19:57:41.397Z
Tech/Game 2022-04-13T10:29:16.535Z

Trends 24h

Tech/Game 2022-08-16T12:52:50.250Z


© Communities 2019 - Privacy